Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Expectations for Next Week

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Oct 07, 2021 7:55pm

149 Views

Post# 33986861

RE:RE:Expectations for Next Week

Can you elaborate, Momo? I don't understand how you are connecting next week's expectations with drug sales 3+ years ago. What am I missing?

-LT

Momo25 wrote: All that good information to justify the failure of the company in achieving their sales objectives for Trogarzo and Egrifta. Unbelievable!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing